Education
About Us
Working with TipRanks
Follow Us
FBT - ETF AI Analysis
Top Page
First Trust NYSE Arca Biotechnology Index Fund (FBT)
Rating:69Neutral
Price Target:
$207.00
Positive Factors
Strong Top Holdings
Several top holdings, such as Alnylam Pharma and Argenx, have shown strong year-to-date performance, supporting the ETF's overall gains.
Solid Year-to-Date Performance
The fund has delivered healthy year-to-date returns, indicating strong momentum in the biotechnology sector.
Reasonable Expense Ratio
The ETF charges a moderate expense ratio, making it relatively cost-effective compared to actively managed funds.
Negative Factors
Sector Concentration Risk
The ETF is heavily concentrated in the health care sector, which increases vulnerability to industry-specific risks.
Geographic Overexposure
Nearly all holdings are U.S.-based, limiting diversification and exposure to international markets.
Underperforming Holdings
Some top holdings, like Bruker and Illumina, have lagged in performance, potentially dragging down overall returns.
FBT vs. SPDR S&P 500 ETF (SPY)
AUM1.26B
RegionNorth America
Expense Ratio0.54%
Beta0.73
IssuerFirst Trust
Inception DateJun 19, 2006
Dividend Yield0.58%
Asset ClassEquity
Index TrackedNYSE Arca Biotechnology Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume27,913
30 Day Avg. Volume16,696
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
229.05Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering31
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
FBT Summary
The First Trust NYSE Arca Biotechnology Index Fund (FBT) is an ETF that focuses on the biotechnology sector, tracking the NYSE Arca Biotechnology Index. It includes innovative companies working on cutting-edge medical advancements, such as genetic engineering and drug development. Some well-known companies in the fund are Exact Sciences and Illumina. Investors might consider FBT for its potential growth opportunities in the health care industry and to diversify their portfolio. However, new investors should be aware that the fund is heavily dependent on the biotech sector, which can be volatile and sensitive to changes in regulations or scientific breakthroughs.
How much will it cost me?The expense ratio for the First Trust NYSE Arca Biotechnology Index Fund (FBT) is 0.54%, which means you’ll pay $5.40 per year for every $1,000 invested. This is higher than average because the fund is actively managed, focusing on a niche sector like biotechnology that requires specialized research and expertise.
What would affect this ETF?The First Trust NYSE Arca Biotechnology Index Fund (FBT) could benefit from advancements in biotechnology and increased demand for innovative medical solutions, especially as the U.S. health care sector continues to grow. However, it may face challenges from regulatory changes, high research costs, or broader economic downturns that could impact funding and investor sentiment in the biotech industry.
FBT Top 10 Holdings
The First Trust NYSE Arca Biotechnology Index Fund (FBT) is riding the wave of innovation in the biotech sector, with standout performers like Alnylam Pharma and Argenx driving gains thanks to strong revenue growth and promising pipeline advancements. Krystal Biotech and Exact Sciences are also contributing steady momentum, supported by strategic expansions and operational growth. However, Illumina and Bruker are holding the fund back, grappling with revenue challenges and bearish sentiment. With nearly all holdings rooted in U.S.-based health care, this ETF is laser-focused on biotech breakthroughs, making it a high-risk, high-reward play for investors chasing transformative medical innovation.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Exact Sciences | 5.21% | $66.17M | $16.33B | 89.69% | 62 Neutral | |
| Natera | 4.02% | $51.10M | $30.14B | 33.18% | 64 Neutral | |
| Regeneron | 3.94% | $50.06M | $73.86B | -1.01% | 81 Outperform | |
| Illumina | 3.83% | $48.73M | $18.35B | -12.94% | 73 Outperform | |
| Bruker | 3.75% | $47.65M | $6.59B | -22.02% | 64 Neutral | |
| Incyte | 3.66% | $46.57M | $19.89B | 44.56% | 81 Outperform | |
| Veracyte | 3.54% | $45.02M | $3.16B | 4.90% | 68 Neutral | |
| Amgen | 3.49% | $44.42M | $184.38B | 15.93% | 77 Outperform | |
| Argenx Se | 3.48% | $44.20M | $56.62B | 53.92% | 79 Outperform | |
| Biogen | 3.46% | $44.00M | $24.64B | 6.44% | 74 Outperform |
FBT Technical Analysis
Positive
―
Price Trends
188.01
Positive
178.32
Positive
171.25
Positive
Market Momentum
4.10
Negative
68.50
Neutral
70.75
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For FBT, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 195.71, equal to the 50-day MA of 188.01, and equal to the 200-day MA of 171.25, indicating a bullish trend. The MACD of 4.10 indicates Negative momentum. The RSI at 68.50 is Neutral, neither overbought nor oversold. The STOCH value of 70.75 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FBT.
FBT Peer Comparison
Comparison Results
Performance Comparison
FBT
First Trust NYSE Arca Biotechnology Index Fund
201.84
34.14
20.36%
XBI
SPDR S&P BIOTECH ETF
―
―
―
IBB
iShares Biotechnology ETF
―
―
―
IHI
iShares U.S. Medical Devices ETF
―
―
―
IYH
iShares U.S. Healthcare ETF
―
―
―
FHLC
Fidelity MSCI Health Care Index ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents